252 related articles for article (PubMed ID: 23123670)
1. Neutral solution low in glucose degradation products is associated with less peritoneal fibrosis and vascular sclerosis in patients receiving peritoneal dialysis.
Kawanishi K; Honda K; Tsukada M; Oda H; Nitta K
Perit Dial Int; 2013; 33(3):242-51. PubMed ID: 23123670
[TBL] [Abstract][Full Text] [Related]
2. Effects of bicarbonate/lactate solution on peritoneal advanced glycosylation end-product accumulation.
Park MS; Kim JK; Holmes C; Weiss MF
Perit Dial Int; 2000; 20 Suppl 5():S33-8. PubMed ID: 11229610
[TBL] [Abstract][Full Text] [Related]
3. Effect of balance Solution on the Peritoneal Membrane in Automated Peritoneal Dialysis.
De Los Ríos T; Pérez-Martínez J; Portoles J; Lichodziejewska-Niemierko M; Rivera M; Nowicki M; Książek A; Tato AM; Bohnhorst C; Feriani M
Perit Dial Int; 2016 9-10; 36(5):569-72. PubMed ID: 27659931
[TBL] [Abstract][Full Text] [Related]
4. Low-GDP, pH-neutral solutions preserve peritoneal endothelial glycocalyx during long-term peritoneal dialysis.
Sugiyama N; Tawada M; Sun T; Suzuki Y; Kinashi H; Yamaguchi M; Katsuno T; Aten J; Vlahu CA; van Kuppevelt TH; Takei Y; Ishimoto T; Maruyama S; Mizuno M; Ito Y
Clin Exp Nephrol; 2021 Sep; 25(9):1035-1046. PubMed ID: 33999275
[TBL] [Abstract][Full Text] [Related]
5. Effects of neutral pH and reduced glucose degradation products in a new peritoneal dialysis solution on morphology of peritoneal membrane in rats.
Ikehara O; Nishimura H; Naito T; Higuchi C; Sanaka T
Nephron Exp Nephrol; 2005; 100(1):e30-9. PubMed ID: 15731567
[TBL] [Abstract][Full Text] [Related]
6. Advanced glycation end products are associated with immature angiogenesis and peritoneal dysfunction in patients on peritoneal dialysis.
Nakano T; Mizumasa T; Kuroki Y; Eriguchi M; Yoshida H; Taniguchi M; Masutani K; Tsuruya K; Kitazono T
Perit Dial Int; 2020 Jan; 40(1):67-75. PubMed ID: 32063152
[TBL] [Abstract][Full Text] [Related]
7. Neutral pH and low-glucose degradation product dialysis fluids induce major early alterations of the peritoneal membrane in children on peritoneal dialysis.
Schaefer B; Bartosova M; Macher-Goeppinger S; Sallay P; Vörös P; Ranchin B; Vondrak K; Ariceta G; Zaloszyc A; Bayazit AK; Querfeld U; Cerkauskiene R; Testa S; Taylan C; VandeWalle J; Yap Y; Krmar RT; Büscher R; Mühlig AK; Drozdz D; Caliskan S; Lasitschka F; Fathallah-Shaykh S; Verrina E; Klaus G; Arbeiter K; Bhayadia R; Melk A; Romero P; Warady BA; Schaefer F; Ujszaszi A; Schmitt CP
Kidney Int; 2018 Aug; 94(2):419-429. PubMed ID: 29776755
[TBL] [Abstract][Full Text] [Related]
8. Effect of glucose degradation products on the peritoneal membrane in a chronic inflammatory infusion model of peritoneal dialysis in the rat.
Park SH; Lee EG; Kim IS; Kim YJ; Cho DK; Kim YL
Perit Dial Int; 2004; 24(2):115-22. PubMed ID: 15119632
[TBL] [Abstract][Full Text] [Related]
9. BIOKID: randomized controlled trial comparing bicarbonate and lactate buffer in biocompatible peritoneal dialysis solutions in children [ISRCTN81137991].
Nau B; Schmitt CP; Almeida M; Arbeiter K; Ardissino G; Bonzel KE; Edefonti A; Fischbach M; Haluany K; Misselwitz J; Kemper MJ; Rönnholm K; Wygoda S; Schaefer F;
BMC Nephrol; 2004 Oct; 5():14. PubMed ID: 15485574
[TBL] [Abstract][Full Text] [Related]
10. Accumulation of advanced glycation end products and beta 2-microglobulin in fibrotic thickening of the peritoneum in long-term peritoneal dialysis patients.
Nakamoto H; Hamada C; Shimaoka T; Sekiguchi Y; Io H; Kaneko K; Horikoshi S; Tomino Y
J Artif Organs; 2014 Mar; 17(1):60-8. PubMed ID: 24337623
[TBL] [Abstract][Full Text] [Related]
11. Accumulation of advanced glycation end products in the peritoneal vasculature of continuous ambulatory peritoneal dialysis patients with low ultra-filtration.
Honda K; Nitta K; Horita S; Yumura W; Nihei H; Nagai R; Ikeda K; Horiuchi S
Nephrol Dial Transplant; 1999 Jun; 14(6):1541-9. PubMed ID: 10383022
[TBL] [Abstract][Full Text] [Related]
12. Biocompatible dialysis fluids for peritoneal dialysis.
Cho Y; Johnson DW; Craig JC; Strippoli GF; Badve SV; Wiggins KJ
Cochrane Database Syst Rev; 2014 Mar; (3):CD007554. PubMed ID: 24671928
[TBL] [Abstract][Full Text] [Related]
13. Strategies to reduce glucose exposure in peritoneal dialysis patients.
Holmes CJ; Shockley TR
Perit Dial Int; 2000; 20 Suppl 2():S37-41. PubMed ID: 10911641
[TBL] [Abstract][Full Text] [Related]
14. Evidence for Biocompatible Peritoneal Dialysis Solutions.
Nataatmadja M; Cho Y; Johnson DW
Contrib Nephrol; 2017; 189():91-101. PubMed ID: 27951555
[TBL] [Abstract][Full Text] [Related]
15. Peritoneal accumulation of advanced glycosylation end-products in diabetic rats on dialysis with icodextrin.
Lee JH; Reddy DK; Saran R; Moore HL; Twardowski ZJ; Nolph KD; Khanna R
Perit Dial Int; 2000; 20 Suppl 5():S39-47. PubMed ID: 11229611
[TBL] [Abstract][Full Text] [Related]
16. Biocompatibility of peritoneal dialysis fluid and influence of compositions on peritoneal fibrosis.
Higuchi C; Nishimura H; Sanaka T
Ther Apher Dial; 2006 Aug; 10(4):372-9. PubMed ID: 16911191
[TBL] [Abstract][Full Text] [Related]
17. Peritoneal equilibration test with conventional 'low pH/high glucose degradation product' or with biocompatible 'normal pH/low glucose degradation product' dialysates: does it matter?
Van Overmeire L; Goffin E; Krzesinski JM; Saint-Remy A; Bovy P; Cornet G; Bovy C
Nephrol Dial Transplant; 2013 Jul; 28(7):1946-51. PubMed ID: 23223220
[TBL] [Abstract][Full Text] [Related]
18. Superior patient survival for continuous ambulatory peritoneal dialysis patients treated with a peritoneal dialysis fluid with neutral pH and low glucose degradation product concentration (Balance).
Lee HY; Park HC; Seo BJ; Do JY; Yun SR; Song HY; Kim YH; Kim YL; Kim DJ; Kim YS; Ahn C; Kim MJ; Shin SK
Perit Dial Int; 2005; 25(3):248-55. PubMed ID: 15981773
[TBL] [Abstract][Full Text] [Related]
19. PPAR-γ agonist rosiglitazone protects peritoneal membrane from dialysis fluid-induced damage.
Sandoval P; Loureiro J; González-Mateo G; Pérez-Lozano ML; Maldonado-Rodríguez A; Sánchez-Tomero JA; Mendoza L; Santamaría B; Ortiz A; Ruíz-Ortega M; Selgas R; Martín P; Sánchez-Madrid F; Aguilera A; López-Cabrera M
Lab Invest; 2010 Oct; 90(10):1517-32. PubMed ID: 20531289
[TBL] [Abstract][Full Text] [Related]
20. Effect of neutral pH and low-glucose degradation product-containing peritoneal dialysis solution on residual renal function in peritoneal dialysis patients: a meta-analysis.
Wang J; Zhu N; Yuan W
Nephron; 2015; 129(3):155-63. PubMed ID: 25765060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
